Eculizumab Treatment for Postpartum HELLP Syndrome and aHUS—Case Report

Show simple item record

dc.contributor.author Lokki, A. Inkeri
dc.contributor.author Haapio, Mikko
dc.contributor.author Heikkinen-Eloranta, Jenni
dc.date.accessioned 2020-05-27T05:32:01Z
dc.date.available 2020-05-27T05:32:01Z
dc.date.issued 2020-04-03
dc.identifier.citation Lokki , A I , Haapio , M & Heikkinen-Eloranta , J 2020 , ' Eculizumab Treatment for Postpartum HELLP Syndrome and aHUS—Case Report ' , Frontiers in Immunology , vol. 11 , 548 . https://doi.org/10.3389/fimmu.2020.00548
dc.identifier.other PURE: 135691297
dc.identifier.other PURE UUID: 5622a7a7-952e-4653-838a-8d89e824b12e
dc.identifier.other RIS: urn:F49E45AAFF0F75C6D29A1E94444A2C3F
dc.identifier.other WOS: 000528680000001
dc.identifier.other ORCID: /0000-0003-4397-8415/work/75464069
dc.identifier.uri http://hdl.handle.net/10138/315267
dc.description.abstract Preeclampsia is a pregnancy-specific disorder affecting ca 3% of all pregnant women. Preeclampsia is the source of severe pregnancy complications. Later life consequences for mother and infant include increased risk of cardiovascular disease. Preeclampsia is caused by the dysfunction of the endothelium with subsequent activation of complement and coagulation systems. HELLP syndrome is considered to be an extreme complication of preeclampsia but it can also present independently. Diagnostic symptoms in HELLP syndrome are Hemolysis, Elevated Liver enzymes, and Low Platelets. Similar phenotype is present in thrombotic microangiopathies (TMAs) and HELLP syndrome is considered part of the TMA spectrum. Here, we present a case of severe preeclampsia and HELLP syndrome, which exacerbated rapidly and eventually led to need of intensive care, plasma exchange, and hemodialysis. The patient showed signs of hemolysis, disturbance in the coagulation, and organ damage in liver and kidneys. After comprehensive laboratory testing and supportive care, the symptoms did not subside and treatment with complement C5 inhibitor eculizumab was started. Thereafter, the patient started to recover. The patient had pregnancy-induced aHUS. Earlier initiation of eculizumab treatment may potentially shorten and mitigate the disease and hypothetically decrease future health risks of preeclamptic women. en
dc.format.extent 7
dc.language.iso eng
dc.relation.ispartof Frontiers in Immunology
dc.rights cc_by
dc.rights.uri info:eu-repo/semantics/openAccess
dc.subject 3123 Gynaecology and paediatrics
dc.subject case report
dc.subject preeclampsia
dc.subject aHUS
dc.subject eculizumab
dc.subject HELLP
dc.subject thrombotic microangiopathy
dc.subject ELEVATED LIVER-ENZYMES
dc.subject LOW PLATELET COUNT
dc.subject THROMBOTIC MICROANGIOPATHY
dc.subject COMPLEMENT ACTIVATION
dc.subject ENDOTHELIAL FUNCTION
dc.subject NORMAL-PREGNANCY
dc.subject HEMOLYSIS
dc.subject PREECLAMPSIA
dc.subject WOMEN
dc.subject LINK
dc.title Eculizumab Treatment for Postpartum HELLP Syndrome and aHUS—Case Report en
dc.type Article
dc.contributor.organization Department of Bacteriology and Immunology
dc.contributor.organization University of Helsinki
dc.contributor.organization Helsinki University Hospital Area
dc.contributor.organization TRIMM - Translational Immunology Research Program
dc.contributor.organization Research Programs Unit
dc.contributor.organization Department of Obstetrics and Gynecology
dc.contributor.organization HUS Gynecology and Obstetrics
dc.contributor.organization HUS Abdominal Center
dc.contributor.organization Nefrologian yksikkö
dc.contributor.organization Department of Medicine
dc.contributor.organization Department of Medical and Clinical Genetics
dc.description.reviewstatus Peer reviewed
dc.relation.doi https://doi.org/10.3389/fimmu.2020.00548
dc.relation.issn 1664-3224
dc.rights.accesslevel openAccess
dc.type.version publishedVersion

Files in this item

Total number of downloads: Loading...

Files Size Format View
fimmu_11_00548.pdf 581.6Kb PDF View/Open

This item appears in the following Collection(s)

Show simple item record